EP0950658A1 — 2-Pipirazinone-1-acetic acid dihydrochloride derivative used to inhibit platelet aggregation
Assigned to Takeda Pharmaceutical Co Ltd · Expires 1999-10-20 · 27y expired
What this patent protects
The present invention is to provide a compound of (S)-4-(4-guanidinobenzoylamino)acetyl -3-[3-(4-guanidinobenzoylamino)]propyl-2-oxopiperazine-1-acetic acid dihydrochloride (I) which has potent and durable platelet aggregation inhibiting action, which is highly safe and which has…
USPTO Abstract
The present invention is to provide a compound of (S)-4-(4-guanidinobenzoylamino)acetyl -3-[3-(4-guanidinobenzoylamino)]propyl-2-oxopiperazine-1-acetic acid dihydrochloride (I) which has potent and durable platelet aggregation inhibiting action, which is highly safe and which has superior physical and chemical properties, and production and use thereof. (I) is also used to inhibit cell adhesion.
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.